References
- Miller JD. Leuprolide acetate for the treatment of endometriosis. In: Chadha DR, Buttram VC Jr, eds. Current concepts in endometriosis. New York: Liss, 1990: 337–41
- Meldrum DR, Chang RJ, Lu J, et al. “Medical oophorectomy” using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982; 54(5): 1081–3
- Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 1990; 54(3): 419–27
- Rolland R, van der Heijden PF. Nafarelin versus danazol in the treatment of endometriosis. Am J Obstet Gynecol 1990; 162(2): 586–8
- Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990; 143(1): 68–71
- Santen RJ, Warner B. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate. Urology 1985: 25(2 Suppl): 53–7
- Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989: 33(5 Suppl): 45–52
- Stovall TG, Ling FW, Henry LC, et al. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991: 164(6 Pt 1): 1420–3 (discussion, 1423–5)
- Coddington CC, Collins RL, Shawker TH, et al. Long-acting gonadotropin hormone-releasing hormone analog used to treat leiomyomata uteri. Fertil Steril 1986; 45(5): 624–9
- Letterie GS, Coddington CC, Winkel CA, et al. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 1989; 51(6): 951–6
- Dodson WC, Hughes CL, Whitesides DB, et al. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1987; 65(1): 95–100
- Richardson MR, Njemanze J. Management of severe fibrocystic disease of the breast with leuprolide acetate. Fertil Steril 1990: 54(5): 942–3
- Muse KN, Cetel NS, Futterman LA, et al. The premenstrual syndrome: effects of “medical ovariectomy.” N Engl J Med 1984; 311(21): 1345–9
- Chetkowski RJ, Kruse LR, Nass TE. Improved pregnancy outcome with the addition of leuprolide acetate to gonadotropins for in vitro fertilization. Fertil Steril 1989: 52(2): 250–5
- Gabrilove JL, Levine AC, Kirschenbaum A, et al. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69(3): 629–32
- Manni A, Santen R, Harvey H, et al. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev 1986: 7(1): 89–94
- Mathias JR, Ferguson KL, Clench MH. Debilitating “functional” bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog. Dig Dis Sci 1989; 34(5): 761–6
- Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324(2): 93–103
- Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial. N Engl J Med 1988; 318(8): 485–9
- Korman LB. Treatment of prostate cancer. Clin Pharm 1989; 8(6): 412–24
- Filicori M, Flamigni C. GnRH agonists and antagonists: current clinical status. Drugs 1988; 35(1): 63–82
- Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990: 66(5 Suppl): 1039–44
- Wheeler MD, Styne DM. Drug treatment in precocious puberty. Drugs 1991: 41(5): 717–28
- Tummon IS, Ali A, Pepping ME, et al. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988; 49(5): 792–6
- Cann CE, Henzl M, Burry K, et al. Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn DV, Martin TJ, Meunier PJ, eds. Calcium regulation and bone metabolism: basic and clinical aspects. Vol 9. New York: Elsevier (Excerpta Medica), 1987: 123–7